Guselkumab Improves Disease Activity and Retention in Psoriatic Arthritis
Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.
Guselkumab, an interleukin-23 inhibitor, was associated with significant improvements in disease activity and a high treatment retention rate among patients with psoriatic arthritis (PsA), according to study findings published in ARP Rheumatology.
Although guselkumab has shown efficacy in randomized clinical trials, evidence from routine practice is more limited, particularly beyond short-term follow-up.
To address this gap, researchers conducted a retrospective multicenter cohort study to evaluate the 12-month efficacy, safety, and persistence of guselkumab among adults with PsA who received care across 3 medical centers in Italy.
- The study included 70 patients with PsA who initiated guselkumab due to arthritis activity and had at least 12 months of follow-up.
- At baseline, patients were aged a median of 59 years and 44% were women.
Author's summary: Guselkumab improves PsA disease activity.